Present initial data for RP3
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 4 Feb 2021
- Due
- 31 Dec 2021
- Delivered
- March 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Initial data is expected to be presented in the second half of 2021.”
What we found
Evidence strength A What the grades mean
The company reported initial data from the RP3 Phase 1 monotherapy cohort in March 2022, which falls within the first quarter of 2022 deadline.
-
A Replimune Group, Inc. 10-K filed 2022-05-19
“In March 2022, we reported initial data from the single agent monotherapy cohort of RP3 in superficial and deep tumors exploring two dose levels of RP3, including injections into deep tumors.” ✓ confirmed on the page
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +90 days
- 2 versions
-
Version 1 · original · stated 4 Feb 2021
Deadline 31 Dec 2021 (“in the second half of 2021”) · wording expected
-
Version 2 · stated 4 Nov 2021
Deadline 31 Mar 2022 (“first quarter of 2022”) · wording expected
“initial monotherapy data expected to be presented in the first quarter of 2022”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Present
- Deliverable
- Initial RP3 data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-REPL-023107 · Corrections policy